Approaches in Barriers, Modifications, Route of Administrations, and Formulations of Therapeutic Agents for Brain Delivery

2019 ◽  
pp. 383-401
Author(s):  
Arun Kumar Kotha ◽  
Saikat Ghosh ◽  
Neeraja Komanduri ◽  
Rui Wang ◽  
Subhas Bhowmick ◽  
...  
Keyword(s):  
Therapeutic Agents ◽  
Brain Delivery

scholarly journals Blood-Brain Delivery Methods Using Nanotechnology

Pharmaceutics ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 269 ◽  
Author(s):  
Daniel Teleanu ◽  
Cristina Chircov ◽  
Alexandru Grumezescu ◽  
Adrian Volceanov ◽  
Raluca Teleanu
Keyword(s):  
Multiple Sclerosis ◽  
Carbon Nanotubes ◽  
Drug Development ◽  
Brain Cancer ◽  
Therapeutic Agents ◽  
Brain Delivery ◽  
Delivery Methods ◽  
Selective Permeability ◽  
Blood Brain ◽  
The Brain

Pathologies of the brain, of which brain cancer, Alzheimer’s disease, Parkinson’s disease, stroke, and multiple sclerosis, are some of the most prevalent, and that presently are poorly treated due to the difficulties associated with drug development, administration, and targeting to the brain. The existence of the blood-brain barrier, a selective permeability system which acts as a local gateway against circulating foreign substances, represents the key challenge for the delivery of therapeutic agents to the brain. However, the development of nanotechnology-based approaches for brain delivery, such as nanoparticles, liposomes, dendrimers, micelles, and carbon nanotubes, might be the solution for improved brain therapies.

scholarly journals Endovascular administration of magnetized nanocarriers targeting brain delivery after stroke

2021 ◽  
pp. 0271678X2110288
Author(s):  
Alba Grayston ◽  
Yajie Zhang ◽  
Miguel Garcia-Gabilondo ◽  
Mercedes Arrúe ◽  
Abraham Martin ◽  
...  
Keyword(s):  
Mechanical Thrombectomy ◽  
Superparamagnetic Iron Oxide ◽  
Therapeutic Agents ◽  
Brain Targeting ◽  
Magnetic Targeting ◽  
Brain Delivery ◽  
Endovascular Interventions ◽  
Endovascular Approach ◽  
Multiple Treatments ◽  
New Treatments

The increasing use of mechanical thrombectomy in stroke management has opened the window to local intraarterial brain delivery of therapeutic agents. In this context, the use of nanomedicine could further improve the delivery of new treatments for specific brain targeting, tracking and guidance. In this study we take advantage of this new endovascular approach to deliver biocompatible poly(D-L-lactic-co-glycolic acid) (PLGA) nanocapsules functionalized with superparamagnetic iron oxide nanoparticles and Cy7.5 for magnetic targeting, magnetic resonance and fluorescent molecular imaging. A complete biodistribution study in naïve (n = 59) and ischemic (n = 51) mice receiving intravenous or intraarterial nanocapsules, with two different magnet devices and imaged from 30 min to 48 h, showed an extraordinary advantage of the intraarterial route for brain delivery with a specific improvement in cortical targeting when using a magnetic device in both control and ischemic conditions. Safety was evaluated in ischemic mice (n = 69) showing no signs of systemic toxicity nor increasing mortality, infarct lesions or hemorrhages. In conclusion, the challenging brain delivery of therapeutic nanomaterials could be efficiently and safely overcome with a controlled endovascular administration and magnetic targeting, which could be considered in the context of endovascular interventions for the delivery of multiple treatments for stroke.

Ligand Conjugated Targeted Nanotherapeutics for Treatment of Neurological Disorders

2020 ◽  
Vol 26 (19) ◽  
pp. 2291-2305 ◽  
Author(s):  
Saurabh Mittal ◽  
Muhammad U. Ashhar ◽  
Farheen F. Qizilbash ◽  
Zufika Qamar ◽  
Jasjeet K. Narang ◽  
...  
Keyword(s):  
Neurological Disorders ◽  
Neurological Diseases ◽  
Therapeutic Agents ◽  
Review Article ◽  
Brain Delivery ◽  
Intranasal Route ◽  
First Pass Metabolism ◽  
First Pass ◽  
The Brain ◽  
Pass Metabolism

Background: Human brain is amongst the most complex organs in human body, and delivery of therapeutic agents across the brain is a tedious task. Existence of blood brain barrier (BBB) protects the brain from invasion of undesirable substances; therefore it hinders the transport of various drugs used for the treatment of different neurological diseases including glioma, Parkinson's disease, Alzheimer's disease, etc. To surmount this barrier, various approaches have been used such as the use of carrier mediated drug delivery; use of intranasal route, to avoid first pass metabolism; and use of ligands (lactoferrin, apolipoprotein) to transport the drug across the BBB. Ligands bind with proteins present on the cell and facilitate the transport of drug across the cell membrane via. receptor mediated, transporter mediated or adsorptive mediated transcytosis. Objective: The main focus of this review article is to illustrate various studies performed using ligands for delivering drug across BBB; it also describes the procedure used by various researchers for conjugating the ligands to the formulation to achieve targeted action. Methods: Research articles that focused on the used of ligand conjugation for brain delivery and compared the outcome with unconjugated formulation were collected from various search engines like PubMed, Science Direct and Google Scholar, using keywords like ligands, neurological disorders, conjugation, etc. Results and Conclusion: Ligands have shown great potential in delivering drug across BBB for treatment of various diseases, yet extensive research is required so that the ligands can be used clinically for treating neurological diseases.

Water-soluble amphiphilic ruthenium(ii) polypyridyl complexes as potential light-activated therapeutic agents

2020 ◽  
Vol 56 (65) ◽  
pp. 9332-9335
Author(s):  
Sandra Estalayo-Adrián ◽  
Salvador Blasco ◽  
Sandra A. Bright ◽  
Gavin J. McManus ◽  
Guillermo Orellana ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Cells ◽  
Cellular Uptake ◽  
Therapeutic Agents ◽  
Water Soluble ◽  
Polypyridyl Complexes ◽  
Cervical Cancer Cells

Two new water-soluble amphiphilic Ru(ii) polypyridyl complexes were synthesised and their photophysical and photobiological properties evaluated; both complexes showed a rapid cellular uptake and phototoxicity against HeLa cervical cancer cells.

Flavonoids in adipose tissue inflammation and atherosclerosis: one arrow, two targets

2020 ◽  
Vol 134 (12) ◽  
pp. 1403-1432 ◽  
Author(s):  
Manal Muin Fardoun ◽  
Dina Maaliki ◽  
Nabil Halabi ◽  
Rabah Iratni ◽  
Alessandra Bitto ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Fruits And Vegetables ◽  
Metabolic Diseases ◽  
Therapeutic Agents ◽  
Adipose Tissue Inflammation ◽  
Cellular Mechanisms ◽  
Tissue Inflammation ◽  
Cholesterol Levels ◽  
Naturally Occurring ◽  
Pro Inflammatory Cytokines

Abstract Flavonoids are polyphenolic compounds naturally occurring in fruits and vegetables, in addition to beverages such as tea and coffee. Flavonoids are emerging as potent therapeutic agents for cardiovascular as well as metabolic diseases. Several studies corroborated an inverse relationship between flavonoid consumption and cardiovascular disease (CVD) or adipose tissue inflammation (ATI). Flavonoids exert their anti-atherogenic effects by increasing nitric oxide (NO), reducing reactive oxygen species (ROS), and decreasing pro-inflammatory cytokines. In addition, flavonoids alleviate ATI by decreasing triglyceride and cholesterol levels, as well as by attenuating inflammatory mediators. Furthermore, flavonoids inhibit synthesis of fatty acids and promote their oxidation. In this review, we discuss the effect of the main classes of flavonoids, namely flavones, flavonols, flavanols, flavanones, anthocyanins, and isoflavones, on atherosclerosis and ATI. In addition, we dissect the underlying molecular and cellular mechanisms of action for these flavonoids. We conclude by supporting the potential benefit for flavonoids in the management or treatment of CVD; yet, we call for more robust clinical studies for safety and pharmacokinetic values.

Preparation and analysis of nanocarriers for brain delivery of neuroprotective andrographolide

Planta Medica ◽  
2015 ◽  
Vol 81 (16) ◽  
Author(s):  
C Guccione ◽  
V Piazzini ◽  
MC Bergonzi ◽  
M Oufir ◽  
D Eigenmann ◽  
...  
Keyword(s):  
Brain Delivery

Antithrombotic Therapy for DVT/PE

1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Cost Effective ◽  
Therapeutic Agents ◽  
Great Promise ◽  
Term Therapy ◽  
Low Molecular Weight ◽  
Long Term Therapy

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.

Imaging of central cannabinoid CB1 receptors, a potential target for therapeutic agents in movement disorders

2005 ◽  
Vol 32 (06) ◽  
Author(s):  
G Berding ◽  
U Schneider ◽  
P Gielow ◽  
R Buchert ◽  
WH Knapp ◽  
...  
Keyword(s):  
Movement Disorders ◽  
Therapeutic Agents ◽  
Cb1 Receptors ◽  
Potential Target

Pharmaconutrition: pharmacological approach to nutrition therapy

2014 ◽  
Vol 155 (51) ◽  
pp. 2021-2027
Author(s):  
István Télessy
Keyword(s):  
Fatty Acids ◽  
Nutritional Support ◽  
Pharmacological Action ◽  
Nutrition Therapy ◽  
Therapeutic Agents ◽  
Therapeutic Action ◽  
Treatment Results ◽  
Research Activity ◽  
Therapeutic Modalities ◽  
The Everyday

Reviewing the literature of nutrition therapy one can conclude that during the last decade the pharmacological action of several nutrients has been demonstrated. However, research activity is still at the beginning and it could be verified in a restricted number of nutrients only that in which conditions (illnesses), dose and duration we can expect therapeutic effect in addition to nutrition. The examples of glutamine, arginine, taurine, leucine, ω-3 fatty acids, however, support the possibility that complex reactions and treatment results observed in certain patients are not purely due to nutritional support but the consequence of additional pharmacological action as well. Evaluation of results of therapeutic intervention is especially difficult because in the everyday practice physicians try to use several therapeutic modalities that can be beneficial for the patient. Therefore, retrospective separation of beneficial components of the therapeutic agents is almost impossible. Only well designed, randomized and multicentric studies can verify specific therapeutic action of certain ingredients ie. nutrients. Orv. Hetil., 2014, 155(51), 2021–2027.

Sign in / Sign up

Export Citation Format

Share Document